Taysha Gene Therapies to Participate in Upcoming November Investor Healthcare Conferences

Stifel 2021 Virtual Healthcare Conference on November 15, 2021 at 11:20 am ET

Jefferies London Healthcare Conference November 17, 2021 at 12:20 pm GMT

4^th Annual Evercore ISI HealthCONx Virtual Conference on November 30, 2021 at 4:20 pm ET

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in the Stifel 2021 Virtual Healthcare Conference, Jefferies London Healthcare Conference, and the 4^th Annual Evercore ISI HealthCONx Virtual Conference.

Conference Details:
Event:	Stifel 2021 Virtual Healthcare Conference
Date:	November 15, 2021
Time:	11:20 am ET
Format:	Fireside Chat
Participants:	RA Session II, President, Founder and Chief Executive Officer
	Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
	Kamran Alam, Chief Financial Officer
	Dr. Kimberly Lee, SVP, Corporate Communications and Investor Relations
Event:	Jefferies London Healthcare Conference
Date:	November 17, 2021
Time:	12:20 pm GMT
Format:	Fireside Chat
Participant:	RA Session II, President, Founder and Chief Executive Officer
	Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
	Kamran Alam, Chief Financial Officer
	Dr. Kimberly Lee, SVP, Corporate Communications and Investor Relations
Event:	4^th Annual Evercore ISI HealthCONx Virtual Conference
Date:	November 30, 2021
Time:	4:20 pm ET
Format:	Fireside Chat
Participant:	RA Session II, President, Founder and Chief Executive Officer
	Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
	Kamran Alam, Chief Financial Officer
	Dr. Kimberly Lee, SVP, Corporate Communications and Investor Relations

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.